

Applied Immunological Research Symposium

30 May 2024, Thursday

Main Auditorium, Center for Discovery and Innovation

111 Ideation Way, Nutley, NJ 07110, Or join virtually

Register Now!

The Annual Symposium on Applied Immunological Research at 3i serves as a global nexus for top researchers in the fields of clinical and basic immunology. This year, our symposium will emphasize the current advances in cellular immunotherapy of cancer, focusing on the practical application of insights gleaned from advanced immunological research. The symposium aims to foster innovation and drive progress in cancer immune therapy.

About 3i

The Hackensack Meridian Health (HMH) Center for Discovery and Innovation (CDI) established the **Institute for Immunologic Intervention (3i)** with the goal of advancing research in immunology to combat infections, cancer, and inflammatory diseases by enhancing the human immune system's responses. Comprising a team of expert scientists, including basic researchers, physician-scientists, and clinicians, the 3i focuses on understanding fundamental mechanisms of infectious immunity, tumor immunity, alloimmunity, and autoimmunity in clinical contexts. In close clinical and translational research partnerships with the HMH John Theurer Cancer Center and the Georgetown Lombardi Comprehensive Cancer Center (LCCC), which collectively form one of the national NCI-designated comprehensive cancer centers the 3i aims to apply this knowledge to improve cancer immunotherapy, interventions for autoimmune and alloimmune conditions, and infection prevention. The scientists at 3i cover diverse fields such as cancer immunology, immunotherapy, T cell biology, genetics, and microbiome influence on antitumor immunosurveillance.

Call for Abstracts

Don't miss the chance to present your research in a poster session at our symposium on Immunology. Send us your abstract by **April 15, 2024** and join a vibrant symposium program that is leading the way in Immunology research. We welcome researchers from all backgrounds, sectors, and stages of their careers to take part.



ABSTRACT
DEADLINE

15
APRIL

SPEAKERS

KEYNOTE SPEAKER

Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is also the Director of the Center for Cellular Immunotherapies and the Director of the Parker Institute for Cancer Immunotherapy. He is a pioneer in the field of CAR T-cell therapy for cancer.

INVITED SPEAKERS

Ivan P. Maillard, MD, PhD, holds the position of Professor of Medicine (Hematology-Oncology) at the Perelman School of Medicine at the University of Pennsylvania. Additionally, he is an Investigator of the Abramson Family Cancer Research Institute and a member of the Penn Stem Cell and Xenotransplantation Program. His research is centered around the regulation of normal and malignant hematopoiesis, bone marrow transplantation, and T cell alloimmunity.

Pawel Kalinski, MD, PhD, holds the Jacobs Family Endowed Chair of Immunology, serving as the Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science at Roswell Park Comprehensive Cancer Center. He is also a Professor of Oncology at the University at Buffalo School of Medicine and Biomedical Sciences. His research focuses on the development and clinical evaluation of new cancer immunotherapies involving the modulation of patients' immune systems.

Michael Atkins, MD, serves as the Deputy Director and Professor at the Georgetown Lombardi Comprehensive Cancer Center. He also holds the Scholl Professorship and Vice Chair position in the Department of Oncology at Georgetown University Medical Center. Dr. Atkins is internationally recognized for his leadership in translational and clinical research in melanoma and renal cell carcinoma. Additionally, he practices as a medical oncologist at MedStar Georgetown University Hospital.


Jianhua Yu, PhD, Professor in Hematology & Hematopoietic Cell Transplantation, leads the Natural Killer Cell Biology Research Program at the Hematologic Malignancies Research Institute. His research spans NK cell biology, CAR NK cells, CAR T cells, oncolytic virus, bispecific antibodies, and hematopoietic stem cell transplantation. Focused on basic and translational research, his lab strives to innovate cellular immunotherapy and oncolytic virotherapy for multiple myeloma, acute myeloid leukemia, glioblastoma, and lung cancer treatment.

Martin Gutierrez, MD, is a Medical Oncologist and the Director of the Phase I Program at Hackensack Meridian Health. He specializes in the treatment of lung cancer and other thoracic malignancies, and he is involved in the development of novel targeted therapies and immunotherapies.

ORGANIZERS



Binfeng Lu, PhD
Director, Institute for
Immunologic
Intervention



Yi Zhang, MD, PhD
Co-Director, Institute
for Immunologic
Intervention





Applied Immunological Research Symposium

30 May 2024, Thursday

Agenda

8: 30 AM	8: 45 AM	Welcome and Opening Remarks Introduction by David Perlin (5 min) Introduction by Binfeng Lu (10 min)
8: 45 AM	9: 25 AM	Binfeng Lu, Ph.D <i>“Epithelial Alarmin Cytokines in Tumor Immune Responses”</i>
9: 25 AM	10: 25 AM	KEYNOTE ADDRESS Carl June, MD
10: 25 AM	10: 45 AM	COFFEE BREAK
10: 45 AM	11: 35 AM	Ivan P. Maillard, MD, PhD <i>“Notch signaling in T and B cell immunity: new findings and opportunities”</i>
11: 35 AM	12: 05 PM	Martin Gutierrez, MD
12: 05 PM	1: 30 PM	LUNCH AND POSTER SESSION
1: 30 PM	2: 10 PM	Michael Atkins MD, FAIO, FASCO <i>“Bedside to Bench Translational Immunotherapy Research in Melanoma and Kidney Cancer”</i>
2: 10 PM	2: 50 PM	Pawel Kalinski, MD, PhD <i>“Translating Dendritic Cell Biology into Cancer Therapies”</i>
2: 50 PM	3: 30 PM	Jianhua Yu, PhD, <i>“Innate Immune Cell-Based Cancer Immunotherapy”</i>
3:45 PM	4:00 PM	CLOSING REMARKS